Review 1: "Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination"
This paper claims that, although anti-PF4 antibody levels remain high in VITT patients months after follow-up, it is not associated with increased platelet activation Reviewers found it timely and reliable but in need of minor revisions on its methodology and discussion.
Created on
Sep 14, 2021
Published on
Sep 14, 2021
Cite As
Boonyawat, K. (2021). Review 1: “Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination.” Rapid Reviews Infectious Diseases. https://doi.org/10.1162/2e3983f5.0e4f5e43